Though little is known regarding PTPRD mutation and drug responses in melanoma, previous observations support PTPRD mutations (or those to the functionally related gene PTPRT) as a positive predictor of outcomes in NSCLC patients receiving ICIs in a pooled cohort from three publicly available datasets as well as the TCGA cohort of NSCLC patients52. This evidence concerns the gene PTPRT and melanoma.